Annual Report

Overview

The report describes the company's continued development of its CIZ1B blood test for early-stage lung cancer detection, supported by research partnerships with the University of York and other specialist partners. It presents the company as an early-stage, pre-revenue biotechnology group with ongoing operating losses. The report also includes climate-related disclosures aligned with the four TCFD pillars, while noting that the Group's current environmental impact is limited by its small, largely outsourced operations.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Period: Ends 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services